CD8A and neoplasm: Following a few cycles of C215Fab-SEA treatment, a strong inflammatory response is provoked by the cytotoxic effect of activated Vβ3 CD8+ T cells, releasing tumor (neo)antigens and recruiting non-Vβ3 T cells to the TDLNs, where these cells are primed by APCs that cross-present the released tumor (neo)antigens.